Search research articles
Contact Us
Filters
Showing results (51-60 of 64) with videos related to
Page
of 7
Sort By:
Cells
|
March 1, 2019
Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions
Marina Bagnoli, Ting Yan Shi, Charlie Gourley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 20, 2009
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup
Michael A Bookman, Mark F Brady, William P McGuire, et al.
The Lancet. Oncology
|
April 26, 2017
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
Robert L Coleman, Mark F Brady, Thomas J Herzog, et al.
JAMA Oncology
|
January 1, 2016
Inherited Mutations in Women With Ovarian Carcinoma
Barbara M Norquist, Maria I Harrell, Mark F Brady, et al.
Gynecologic Oncology
|
February 1, 2011
Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations
Robin A Lacour, Shannon N Westin, Larissa A Meyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 2, 2017
Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study
Barbara M Norquist, Mark F Brady, Maria I Harrell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2022
Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial
Joyce F Liu, Mark F Brady, Ursula A Matulonis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2019
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study
Joan L Walker, Mark F Brady, Lari Wenzel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 3, 2024
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005
Jung-Min Lee, Mark F Brady, Austin Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 27, 2022
Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study
Larry J Copeland, Mark F Brady, Robert A Burger, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 64) with videos related to
Sort By:
Page
of 7
Cells
|
March 1, 2019
Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions
Marina Bagnoli, Ting Yan Shi, Charlie Gourley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 20, 2009
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup
Michael A Bookman, Mark F Brady, William P McGuire, et al.
The Lancet. Oncology
|
April 26, 2017
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
Robert L Coleman, Mark F Brady, Thomas J Herzog, et al.
JAMA Oncology
|
January 1, 2016
Inherited Mutations in Women With Ovarian Carcinoma
Barbara M Norquist, Maria I Harrell, Mark F Brady, et al.
Gynecologic Oncology
|
February 1, 2011
Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations
Robin A Lacour, Shannon N Westin, Larissa A Meyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 2, 2017
Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study
Barbara M Norquist, Mark F Brady, Maria I Harrell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2022
Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial
Joyce F Liu, Mark F Brady, Ursula A Matulonis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2019
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study
Joan L Walker, Mark F Brady, Lari Wenzel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 3, 2024
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005
Jung-Min Lee, Mark F Brady, Austin Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 27, 2022
Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study
Larry J Copeland, Mark F Brady, Robert A Burger, et al.
Page
of 7